research use only

Abacavir Reverse Transcriptase inhibitor

Name: Abacavir
Brand: Selleck Chemicals
SKU: S5215
Availability: InStock
Rating: 5 (10 reviews)

Cat.No.S5215

Abacavir is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS.

Chemical Structure

Molecular Weight: 286.33

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite HIV HCV Protease SARS-CoV HIV Protease Influenza Virus β-lactamase Integrase HBV CMV Neuraminidase HCV HSV RSV Enterovirus Thioredoxin Reductase 3C-Like Protease Ribosomal Peptidyl Transferase HPV
Related Products	Dapivirine (TMC120) Salicylanilide Fangchinoline

Chemical Information, Storage & Stability

Molecular Weight	286.33	Formula	C₁₄H₁₈N₆O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	136470-78-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	1592U89			Smiles	C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO

Solubility

In vitro
Batch:

DMSO : 57 mg/mL ( (199.07 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 57 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Reverse transcriptase ^[1]
In vitro	Abacavir (ABC) exhibits potent in vitro antiviral activity against wild-type HIV-1 (IC50 4.0 μM, MT-4 cells)^[1]. This compound induces chromosomal DSBs and thereby kills ATL cells but not non-HTLV-1-infected cells. Once it is incorporated into the cells, it is phosphorylated in a unique stepwise anabolism to be converted to the triphosphated guanine analog carbovir (CBV) and then incorporated into host chromosomal DNA by replicative DNA polymerases, leading to premature termination of DNA replication, collapse of the replication fork, and DSB formation. This chemical induces S/G2-phase arrest and apoptosis in ED-40515(−) cells, but not in Jurkat cells^[2].
In vivo	Abacavir efficiently inhibits the growth of ATL cell xenografts in NOD/SCID mice^[2]. In adults, this compound is rapidly absorbed after oral administration, with peak concentrations occurring 0.63-1 hour after dosing. The absolute bioavailability of abacavir is approximately 83%. Its pharmacokinetics are linear and doseproportional over the range of 300-1200 mg/day. The apparent volume of distribution after intravenous administration is approximately 0.86 ± 0.15 L/kg, suggesting that it is distributed to extravascular spaces. Binding to plasma proteins is about 50% and is independent of the plasma abacavir concentration. This chemical is extensively metabolized by the liver; less than 2% is excreted as unchanged drug in the urine. It is primarily metabolized via two pathways, uridine diphosphate glucuronyltransferase and alcohol dehydrogenase, resulting in the inactive glucuronide metabolite and the inactive carboxylate metabolite. The terminal elimination half-life is approximately 1.5 hours. The antiviral effect is due to its intracellular anabolite, carbovirtriphosphate (CBV-TP). This compound is not significantly metabolized by cytochrome P450 (CYP) enzymes, nor does it inhibit these enzymes^[3].
References	https://pubmed.ncbi.nlm.nih.gov/16305515/ https://pubmed.ncbi.nlm.nih.gov/26601161/ https://pubmed.ncbi.nlm.nih.gov/18479171/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04133012	Completed	HIV-1 Infection	ANRS Emerging Infectious Diseases\|ViiV Healthcare	February 10 2020	Not Applicable
NCT02708342	Completed	HIV	IRCCS San Raffaele\|Merck Sharp & Dohme LLC	April 2016	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):